Personal Genome Diagnostics, a Baltimore-based cancer diagnostics company, said in a regulatory filing it has raised $65 million in an ongoing equity financing round in which it hopes to raise $111.5 million.
Personal Genome Diagnostics, or PGDx, declined comment because the round has not yet closed.
PGDx specializes in analyzing cancer patients’ genes to improve diagnosis and treatment options. The company was founded in 2010 by Dr. Luis Diaz and Dr. Victor Velculescu, leaders in cancer genomics at Johns Hopkins School of Medicine.
In its Oct. 30 filing with the U.S. Securities and Exchange Commission, PGDx said the final amount of the round, expected to close in the coming weeks, could be higher or lower than the $111.5 million target.
As of Oct. 30, it said 12 investors have purchased equity in the company, generating $65 million.
In 2015, PGDx raised $21.4 million in a Series A funding round led by New Enterprise Associates Inc. That came on top of $2.8 million in seed financing.
The company employs 170 people and is based in Canton.